Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
INVA

INVA - Innoviva Inc Stock Price, Fair Value and News

$19.56-0.16 (-0.81%)
Market Closed

75/100

INVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

75/100

INVA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$27.13

Target 3M

$21.22

Target 6M

$23.04

INVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INVA Price Action

Last 7 days

-0.2%

Last 30 days

-0.8%

Last 90 days

9.0%

Trailing 12 Months

4.1%

INVA RSI Chart

INVA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

INVA Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

11.48

Price/Sales (Trailing)

3.76

EV/EBITDA

7.12

Price/Free Cashflow

6.77

INVA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$27.13

Target 3M

$21.22

Target 6M

$23.04

INVA Fundamentals

INVA Revenue

Revenue (TTM)

388.5M

Rev. Growth (Yr)

20.44%

Rev. Growth (Qtr)

7.5%

INVA Earnings

Earnings (TTM)

127.3M

Earnings Growth (Yr)

7.3K%

Earnings Growth (Qtr)

41.17%

INVA Profitability

EBT Margin

40.29%

Return on Equity

12.61%

Return on Assets

8.91%

Free Cashflow Yield

14.77%

INVA Investor Care

Shares Dilution (1Y)

19.44%

Diluted EPS (TTM)

1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025369.8M370.2M388.5M0
2024311.6M330.5M352.7M358.7M
2023317.7M290.4M290.4M310.5M
2022396.4M403.8M373.2M331.3M
2021343.6M365.5M374.7M391.9M
2020284.5M299.4M322.3M336.8M
2019263.8M260.8M264.9M261.0M
2018229.1M237.6M250.7M261.0M
2017149.9M176.0M191.3M217.2M
201671.2M93.0M112.8M133.6M
201516.1M25.8M38.4M53.9M
20145.5M6.5M7.5M8.4M
20135.3M5.1M4.8M4.5M
2012145.3M140.3M135.3M5.6M
201124.3M24.4M24.4M24.5M
201000024.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Innoviva Inc

INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
 WEBSITEinva.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES101

Innoviva Inc Frequently Asked Questions

INVA is the stock ticker symbol of Innoviva Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Innoviva Inc is 1.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check INVA's fair value in chart for subscribers.

The fair value guage provides a quick view whether INVA is over valued or under valued. Whether Innoviva Inc is cheap or expensive depends on the assumptions which impact Innoviva Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INVA.

As of Wed Jan 28 2026, INVA's PE ratio (Price to Earnings) is 11.48 and Price to Sales (PS) ratio is 3.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INVA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Innoviva Inc has provided 0.069 (multiply by 100 for percentage) rate of return.